Enjoy 20% off all recombinant proteins from MedChemExpress and benefit from special pricing on selected additional products. Additionally, save 13% on Ready-to-Use Compound Libraries. Discounts are already reflected in the displayed prices and cannot be combined. Hurry, offer ends May 31, 2026.
Product Description: Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), is an orally active JAK1 and JAK2 inhibitor. Deuruxolitinib demonstrates significant hair regrowth effects. Deuruxolitinib can be used for the research of alopecia areata[1].
Applications: COVID-19-immunoregulation
Formula: C17H10D8N6
References: [1]Brett King, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024 Nov;91(5):880-888./[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
CAS Number: 1513883-39-0
Molecular Weight: 314.41
Compound Purity: 99.18
Research Area: Inflammation/Immunology
Solubility: DMSO : 116.67 mg/mL (ultrasonic)
Target: JAK
Deutsch
English
